Table 4.

IGF-1, crude analysis.

Visit	rhGH, median [IQR]	Placebo, median [IQR]	p-value
Baseline	218.5 ng/mL [147.0, 263.5]	194.0 ng/mL [151.0, 279.0]	0.911
1 Month	272.5 ng/mL [212.5, 354.0]	246.0 ng/mL [197.0, 312.0]	0.337
3 Month	282.0 ng/mL [183.0, 377.0]	213.0 ng/mL [158.0, 259.0]	0.035
6 Month	245.5 ng/mL [203.5, 321.5]	173.0 ng/mL [145.0, 237.0]	0.005
12 Month	185.5 ng/mL [143.0, 252.0]	172.5 ng/mL [148.0, 222.0]	0.836

2-sided p-value from PROC NPAR1WAY Wilcoxon Rank Sum Test; Baseline through 6 Month contain only participants with 6 month follow-up (n = 40; 20 each group); 12 month contains only participants with 12 month follow-up (n = 16 for rhGH, n = 18 for placebo).